Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited].
PMID: 41293705 · 2025
Abstract
Photoacoustic imaging (PAI) combines optical contrast with acoustic detection to enable high-resolution, molecular imaging at clinically relevant depths. This review outlines the current status and future potential of contrast-enhanced PAI in human applications. We begin by discussing regulatory considerations surrounding both imaging devices and exogenous contrast agents, highlighting safety concerns, lack of standardized validation protocols, and barriers to the approval of novel agents. To ac
Official Source
View on PubMed →Data sourced from PubMed / NCBI. For the full text and most current information, always refer to the official record.